Corporate | 31 July 2003 13:41

Evotec OAI AG english

Definiens and Evotec Technologies Partner to Offer Enhanced Technology Solution Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Definiens AG, a leading provider of software solutions for automated pattern recognition in biomedical images and scientific text, together with Evotec Technologies GmbH, a subsidiary of Evotec OAI AG, supplier of innovative technologies for life sciences, today announced an agreement to combine complementary technologies in order to create an informatics-based system designed to help accelerate drug discovery and development. Evotec Technologies (ET) has generated an interface for Definiens Cellenger to ETs software technology platform Libretto. Cellenger is a software for powerful automated high content analysis of tissues and cellular assays that enables the reliable and fully automated extraction and detailed analysis of structures of interest even in complex image data and tasks. The extracted objects are then counted or morphometrically measured. In contrast to a more qualitative, global assessment of an image, as is the case with a visual analysis, a detailed, quantitative description of, e.g. tissue substructures, can now be obtained. This new relationship offers scientists a comprehensive and integrated solution for robust, detailed and high throughput screening of assays in cell biology. In particular, ET’s confocal microplate analyser for high quality image detection (Opera) will take advantage of this innovative software solution. “The value added which is achieved by automated, detailed, context sensitive, reliable, and fast analysis of theses images can not be underestimated,” said Uli Berresheim, CEO of Definiens AG. “We are going to create a system that will automatically provide the user with valuable information about cells, cell components, and their mutual relations. The synergy between the quality of images provided by Opera and the detailed analysis and quantification achieved through Cellenger is outstanding.” “The cooperation with Definiens is a further important step towards developing and manufacturing our products with competent strategic partners. Cellenger further extends Opera’s capabilities as an open platform for cell biology experimentation, and with our open software architecture we could implement this extension quickly” said Dr. Rolf Günther, CSO of Evotec Technologies. The joint solution will be available by the end of September 2003. Further information about Definiens and Evotec Technologies, as well as their complete respective product ranges, can be found on the following websites: www.definiens.com and www.evotec-technologies.com About Evotec Technologies GmbH Evotec Technologies GmbH (ET) is a subsidiary of Evotec OAI focussed on technology development and instrumentation. ET has established a powerful engine for converting customers’ needs from prototypes into industrialised applications for life sciences laboratories. The Company provides state-of-the- art automated and miniaturised processes that result in extremely high data content and quality output by seamlessly integrating hardware, software and bioware modules. ET’s current portfolio comprises its established uHTS EVOscreen system for large pharmaceutical companies and a product line of innovative bench-top instruments, consumables and reagents. These solutions are based on its broad patent portfolio, scientific excellence – from drug discovery to diagnostics – and technical know-how. ET’s particular strengths are in detection and analysis in molecular dimensions, liquid handling of minimal volumes and high-speed interpretation methods and software. Evotec Technologies employs 80 people, primarily at its main site in Hamburg, Germany. Subsidiaries are located in Düsseldorf and Berlin. About Definiens AG Definiens is a leading provider of software solutions for automated pattern recognition in biomedical images and scientific documents. Based on Definiens Cognition Network Technology, a fundamental technology which models human thought, Definiens products enable the extraction of knowledge from biomedical images and scientific texts. Main applications are in drug research and other biopharmaceutical processes. Definiens customers in the field of life sciences are companies such as Academia, Altana, Aventis, Intervet, Merck, NGFN, and Novo Nordisk. Founded in 1994 by Nobel Prize Laureate Prof. Dr. Gerd Binnig, Definiens today has 40 employees and is based in Munich, Germany. For further information regarding the company and its products please visit www.definiens.com. Press contact: AMB Media Andrea Müller-Beilschmidt Phone +49 (0)89 66 50 07 66 Mobile +49 (0)171 76 66 518 Fax +49 (0)89 66 50 07 68 Email: pr@definiens.com info@amb-media.de Evotec Technologies GmbH Dr. Martin Daffertshofer Phone +49 (0)40 560 81 283 Fax +49 (0)40 560 81 488 Email: martin.daffertshofer@evotec-technologies.com end of message, (c)DGAP 31.07.2003 ——————————————————————————– WKN: 566480; ISIN: DE0005664809; Index: TecDAX, NEMAX 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 311341 Jul 03